氯噻酮与氢氯噻嗪对高血压患者肾脏结局的影响:一项随机临床试验的二次分析
该研究为利尿剂比较项目(Diuretic Comparison Project)的预设二次分析,纳入12265例≥65岁、正在服用氢氯噻嗪的高血压退伍军人,随机分为继续氢氯噻嗪或换用氯噻酮,平均随访3.9年。主要肾脏结局(血肌酐翻倍、终末期eGFR<15 mL/min或启动透析)在氯噻酮组6.0%、氢氯噻嗪组6.4%,HR 0.94(95%CI 0.81-1.08;P=0.37),氯噻酮未优于氢氯噻嗪。以eGFR下降≥40%替代肌酐翻倍或任一复合终点组分,结果相似;CKD发生率(21.3% vs 20.8%;P=0.59)和需住院的急性肾损伤(6.4% vs 6.2%;P=0.63)均无差异。但氯噻酮组低钾血症发生率显著更高(8.9% vs 6.9%;P<0.001)。作者认为,临床医生可放心使用这两种药物治疗高血压并关注肾脏结局。
要点
- 在≥65岁高血压退伍军人中,氯噻酮与氢氯噻嗪的主要肾脏复合结局无差异:6.0% vs 6.4%,HR 0.94(95%CI 0.81-1.08;P=0.37)。
- 以eGFR下降≥40%替代血肌酐翻倍,或单独分析任一复合终点组分,结果与主要分析相似。
- CKD发生率(21.3% vs 20.8%;P=0.59)与需住院的急性肾损伤(6.4% vs 6.2%;P=0.63)两组均无差异。
- 氯噻酮组低钾血症发生率显著高于氢氯噻嗪组(8.9% vs 6.9%;P<0.001)。
- 作者认为,鉴于上述 findings,临床医生可放心使用这两种药物治疗高血压并关注肾脏结局。
适用人群与场景
- ≥65岁、正在服用氢氯噻嗪的高血压退伍军人,来自全美退伍军人事务部设施。
- 分析纳入12265例(90.7%)有基线及至少1次随访血肌酐测量的参与者;中位(IQR)年龄71(69-75)岁;女性3.2%、男性96.8%。
诊断标准与关键阈值
- 主要肾脏结局为CKD进展,定义为血肌酐较基线翻倍、终末期估算肾小球滤过率(eGFR)<15 mL/min或启动透析。
研究设计与关键结果
- 研究类型:利尿剂比较项目(Diuretic Comparison Project)的预设二次分析,该试验为随机临床试验,比较氯噻酮与氢氯噻嗪治疗高血压;2016年6月1日至2022年6月1日通过全美退伍军人事务部设施开展,本分析随访延长至2023年12月31日。
- 随机分组:13523例参与者被随机分配继续氢氯噻嗪或换用氯噻酮;本分析纳入12265例(90.7%)有基线及至少1次随访血肌酐测量者。
- 平均(SD)研究时长3.9(1.3)年。
- 主要肾脏结局:氯噻酮组369/6118(6.0%) vs 氢氯噻嗪组396/6147(6.4%);HR 0.94(95%CI 0.81-1.08;P=0.37),氯噻酮未优于氢氯噻嗪。
- 以eGFR下降≥40%替代血肌酐翻倍,或分析主要复合结局的任一组分,结果相似。
- CKD发生率:氯噻酮组961/4520(21.3%) vs 氢氯噻嗪组939/4518(20.8%);P=0.59。
- 需住院的急性肾损伤:氯噻酮组391例(6.4%) vs 氢氯噻嗪组379例(6.2%);P=0.63。
- 低钾血症发生率:氯噻酮组545例(8.9%) vs 氢氯噻嗪组426例(6.9%);P<0.001,氯噻酮组显著升高。
证据类型、等级与局限
- 证据类型:随机临床试验的预设二次分析。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,鉴于上述 findings,临床医生可放心使用氯噻酮或氢氯噻嗪治疗高血压并关注肾脏结局。
- 使用氯噻酮时需注意低钾血症发生率高于氢氯噻嗪(8.9% vs 6.9%;P<0.001)。
指南或共识出处
- Diuretic Comparison Project(临床试验注册号NCT02185417)。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
IMPORTANCE: Hypertension is a risk factor for the development and progression of chronic kidney disease (CKD). It is unclear whether different thiazide diuretics have a differential impact on kidney outcomes.
OBJECTIVE: To compare kidney outcomes in patients with hypertension taking chlorthalidone and hydrochlorothiazide.
DESIGN, SETTING, AND PARTICIPANTS: This prespecified secondary analysis of the Diuretic Comparison Project, a randomized clinical trial comparing chlorthalidone and hydrochlorothiazide for the treatment of hypertension, was conducted between June 1, 2016, and June 1, 2022, through Veterans Affairs facilities nationwide. This analysis extended follow-up to December 31, 2023. Veterans 65 years or older with hypertension who were taking hydrochlorothiazide were included.
INTERVENTION: The Diuretic Comparison Project randomized 13 523 participants to continue hydrochlorothiazide or switch to chlorthalidone.
MAIN OUTCOME AND MEASURES: The main kidney outcome was CKD progression, defined as doubling of serum creatinine level from baseline, a terminal estimated glomerular filtration rate (eGFR) less than 15 mL/min, or dialysis initiation.
RESULTS: Analysis included 12 265 participants (90.7%) with a baseline and 1 or more follow-up creatinine measurements (median [IQR] age, 71 [69-75] years; 3.2% female and 96.8% male). The mean (SD) study duration was 3.9 (1.3) years. Chlorthalidone was not superior to hydrochlorothiazide at preventing kidney outcomes (369 of 6118 [6.0%] vs 396 of 6147 [6.4%]; hazard ratio [HR], 0.94; 95% CI, 0.81-1.08; P = .37). Similar results were observed when a 40% or greater reduction of eGFR was substituted for doubling of creatinine in the above outcome, as well as any of the components of the primary composite outcome. There was no difference in the incidence of CKD (961 of 4520 [21.3%] for chlorthalidone vs 939 of 4518 [20.8%] for hydrochlorothiazide; P = .59) or acute kidney injury requiring hospitalization (391 [6.4%] for chlorthalidone vs 379 [6.2%] for hydrochlorothiazide; P = .63) between groups. However, a statistically significant increased incidence of hypokalemia for chlorthalidone vs hydrochlorothiazide was observed (545 [8.9%] vs 426 [6.9%]; P < .001).
CONCLUSIONS AND RELEVANCE: Chlorthalidone was not superior to hydrochlorothiazide for kidney outcomes but was associated with an increased risk for hypokalemia. Given these findings, clinicians should feel confident using either agent for the treatment of hypertension and kidney outcomes.
TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02185417.
参考来源
- Ishani A, Hau C, Raju S, et al. Chlorthalidone vs Hydrochlorothiazide and Kidney Outcomes in Patients With Hypertension: A Secondary Analysis of a Randomized Clinical Trial. JAMA Netw Open. 2024. PMID: 39656458. doi:10.1001/jamanetworkopen.2024.49576
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。